Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Marisa C, Tewari, Krishnansu S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310180/
https://www.ncbi.nlm.nih.gov/pubmed/30627206
http://dx.doi.org/10.7573/dic.212558
_version_ 1783383399234273280
author Liu, Marisa C
Tewari, Krishnansu S
author_facet Liu, Marisa C
Tewari, Krishnansu S
author_sort Liu, Marisa C
collection PubMed
description Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.
format Online
Article
Text
id pubmed-6310180
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-63101802019-01-09 Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations Liu, Marisa C Tewari, Krishnansu S Drugs Context Review Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from. BioExcel Publishing Ltd 2018-12-27 /pmc/articles/PMC6310180/ /pubmed/30627206 http://dx.doi.org/10.7573/dic.212558 Text en Copyright © 2018 Liu MC, Tewari KS. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Review
Liu, Marisa C
Tewari, Krishnansu S
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
title Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
title_full Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
title_fullStr Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
title_full_unstemmed Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
title_short Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
title_sort anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310180/
https://www.ncbi.nlm.nih.gov/pubmed/30627206
http://dx.doi.org/10.7573/dic.212558
work_keys_str_mv AT liumarisac antiangiogenesistherapysyntheticlethalityandcheckpointinhibitioninovariancancerstateofthescienceandnovelcombinations
AT tewarikrishnansus antiangiogenesistherapysyntheticlethalityandcheckpointinhibitioninovariancancerstateofthescienceandnovelcombinations

Ejemplares similares